Feasibility and acceptability of conducting HIV vaccine trials in adolescents in South Africa: Going beyond willingness to participate towards implementation

M Wallace, BSocSci Hons, MSc, PhD; K Middelkoop, MD, PhD; P Smith, MSocSci; C Pike, BSocSci Hons, MSc; T Bennie, MA; J Chandia, MB ChB, DTM&H, DPH, DIPHC, MPraxMed, FCFF, PhD; G Churchyard, MB ChB, FCPath; G Gray, MB ChB, FCPath, DSc; M H Latka, PhD, MPH; M Mathebula, MB ChB; M Nhlabeng, MB ChB, MMed (Micro); S Roux, MB ChB, MPH; C Slack, MA (Clin Psych), PhD; A Strode, BA, LLB, LLM; L-G Bekker, MB ChB, DCH, DTM&H, FCP (SA), PhD

Background. HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in sub-Saharan Africa HIV-related deaths continue to rise in this age group despite a decline in both adult and paediatric populations. This is attributable in part to high adolescent infection rates and supports the urgent need for more efficacious prevention strategies. In particular, an even partially effective HIV vaccine, given prior to sexual debut, is predicted to significantly curb adolescent infection rates. While adolescents have indicated willingness to participate in HIV vaccine trials, there are concerns around safety, uptake, adherence, and ethical and logistic issues.

Objectives. To initiate a national, multisite project with the aim of identifying obstacles to conducting adolescent HIV vaccine trials in South Africa (SA).

Method. A simulated HIV vaccine trial was conducted in adolescents aged 12 - 17 years across five SA research sites, using the already licensed Merck human papillomavirus vaccine Gardasil as a proxy for an HIV vaccine. Adolescents were recruited at community venues and, following a vaccine discussion group, invited to participate in the trial. Consent for trial enrolment was obtained from a parent or legal guardian, and participants aged 16 - 17 years were eligible only if sexually active. Typical vaccine trial procedures were applied during the five study visits, including the administration of vaccination injections at visit studies 2, 3 and 4.

Results. The median age of participants was 14 years (interquartile range 13 - 15), with 81% between the ages of 12 and 15 years at enrolment. Overall, 98% of screened participants opted to receive the vaccine, 588 participants enrolled, and 524 (89%) attended the final visit.

Conclusions. This trial showed that adolescents can be recruited, enrolled and retained in clinical prevention trials with parental support. While promising, these results were tempered by the coupling of sexual-risk eligibility criteria and the requirement for parental/guardian consent, which was probably a barrier to the enrolment of high-risk older adolescents. Further debate around appropriate consent approaches for such adolescents in HIV prevention studies is required.


Adolescents (aged 15 - 24 years) remain at the centre of the HIV/AIDS epidemic in terms of infection rates, vulnerability and impact, with the Joint United Nations Programme on HIV/AIDS (UNAIDS) reporting 4 million adolescents living with HIV globally in 2016. In eastern and southern Africa, young women and adolescent girls are disproportionately affected. Despite their recognition as a high-priority group for HIV prevention, there was only a 6% drop in new infections among adolescent females between 2010 and 2015. South Africa (SA) has one of the highest HIV prevalence rates in the world, with an estimated 18.9% of the population aged 15 - 49 years infected. HIV incidence rates for women peak in the 15 - 24-year age group, while men reach peak rates 5 - 7 years later. Individuals who acquire HIV infection at a young age have a greater probability of transmitting the virus than those who are infected when older, making the deployment of efficacious prevention strategies to adolescent females an urgent and compelling priority. Vaccination is the preferred prevention method for viral infections, and HIV vaccination prior to sexual debut has been identified as a
potential means of curbing the epidemic.\textsuperscript{7,11} Simultaneous licensure of an efficacious prophylactic HIV vaccine for both adults and adolescents is important; however, testing of a candidate vaccine in adolescent populations is likely to be required for age-specific licensure.\textsuperscript{13,40} Compared with adults, adolescents may exhibit different vaccination-induced immune responses and safety profiles, and show differences in vaccine uptake and effectiveness.\textsuperscript{14} While vaccine safety and efficacy is a biomedical concern, broader issues relating to adolescent participation in clinical trials must be considered, including uptake, ethical, sociobehavioural and logistic challenges.\textsuperscript{15-17}

To date, no clinical HIV vaccine trials have involved adolescents, although a number of preparatory and acceptability studies have been reported. This work has focused on the acceptability of a preventive HIV vaccine\textsuperscript{18-20} and of adolescent participation in vaccine trials.\textsuperscript{21-23} Proposed models of adolescent inclusion in HIV vaccine trials suggest that the eligibility age for study participants may be rolled down to 16 - 18 years once safety and immunogenicity are established in adult efficacy trials, along with phase 1 - 2 bridging safety and immunogenicity trials for younger age groups. Research conducted in SA indicates that hypothetical willingness for adolescent participation in vaccine trials is high for various reasons, but concerns remain.\textsuperscript{24-26} Several studies have also focused on issues relating to feasibility of research in adolescents, including the viability of recruiting high-risk adolescents for efficacy trials. Most have used observational cohorts where the intervention is HIV testing and incidence and retention are the main outcomes.\textsuperscript{27-29} While these studies provide useful preliminary data, it is important to note their limitations. Attitudes alone are unlikely to predict behaviour, and the value of examining ‘willingness to participate’ in a vaccine trial and its predictors is therefore limited.\textsuperscript{30} Additionally, recruiting an observational cohort may not adequately reflect challenges arising from providing an experimental product to adolescents in a clinical setting.

Objectives

In order to develop an authentic understanding of the issues related to running HIV vaccine trials in adolescents, we initiated a national, multisite project with the broad objective of identifying clinical, community, ethical, legal and sociobehavioural obstacles to the conduct of adolescent HIV vaccine trials in SA and building capacity to address these, through the enactment of a simulated HIV vaccine trial. This study used the Merck human papillomavirus (HPV) vaccine Gardasil, already licensed but not yet available at the time, as a proxy for an HIV vaccine in adolescents in SA. The use of a registered vaccine with established safety and immunogenicity enabled focus on key feasibility questions such as recruitment, consent, retention, uptake and completion of a vaccine schedule; risk behaviours and HIV, sexually transmitted infection (STI) and pregnancy incidence in the cohort; and exploration of models for adolescent inclusion in HIV vaccine trials.

Methods

The study was a multisite, open-label longitudinal cohort of 12 - 17-year-old, HIV-negative male and female adolescents. Sites at five SA HIV research organisations participated in this study: Desmond Tutu HIV Foundation, Cape Town; CAPRISA (Centre for the AIDS Programme of Research in South Africa), Durban; Perinatal HIV Research Unit, Soweto; MeCRU Clinical Research Unit, Pretoria; and The Aurum Institute, Rustenberg. These research sites are located in low-income, rural and urban areas with high HIV incidence rates. Adolescents were recruited through community outreach by targeting schools, youth groups, taxi ranks and other points of community convergence. Adolescents were also reached through their parents via outreach recruitment leaflets and activities.

Throughout, procedures simulating those of a typical HIV vaccine trial were adhered to as far as possible. Adolescents and parents were invited to attend vaccine discussion groups (VDGs) where information was provided on study procedures (including randomisation and blinding concepts to replicate an actual vaccine trial), HPV and the HPV vaccine. Following the VDG, attendees were invited to attend a screening visit. The age of consent to health research in SA is 18 years, and as the age eligibility criterion was 17 at screening, all potential participants were therefore required to sign assent forms after their parent/guardian signed a consent form for their child’s enrolment. Both completed a questionnaire that assessed understanding of the study objectives and procedures, where continuation of study participation was dependent on achievement above a minimum score threshold. This assessment of understanding was re-administered to participants at the end of the study (month 9).

All participants were required to be HIV-negative at screening, and females could not be pregnant or breastfeeding. In order to simulate the potential requirements of an HIV vaccine trial, participants aged ≥16 years (the age at which adolescents can lawfully consent to sex in SA) were required to be sexually active (defined as ever having had vaginal or anal sex). Sexual debut was not required as an eligibility criterion in youth aged 12 - 15 years. Sexually active females were encouraged to use hormonal and/or barrier contraception throughout the vaccine schedule, and both contraceptive methods were provided to participants. To safeguard adolescent privacy, parents/guardians were clearly told which clinical information they would and would not be party to as the trial continued.\textsuperscript{12,31} Adolescents meeting the study criteria were enrolled and opted (with parental/guardian consent) to receive the HPV vaccine or not. Both those receiving and those not receiving the vaccine underwent identically study procedures apart from vaccine administration, such as perceived risks and benefits, age, gender, and knowledge of disease and vaccine, in order to determine correlates between vaccine uptake and refusal.

Participants attended five visits in total: screening, enrolment within 45 days of screening (first administration of vaccine), 3 months (second administration of vaccine), 6 months (final administration of vaccine), and 9 months (final follow-up including an assessment of study understanding). At each visit, HIV counselling and testing, syphilis screening and pregnancy testing for females were conducted and sexual risk behaviour was assessed. STI symptoms were recorded at every visit. HIV testing utilised rapid finger-prick antibody-based tests and followed national HIV testing guidelines,\textsuperscript{32} while an RPR (rapid plasma reagin) test was used to screen for syphilis. The HPV vaccine schedule was paused for females who became pregnant after enrolment, but was continued for participants who seroconverted during the study. Sexual risk behaviour was assessed through a quantitative questionnaire designed specifically for this study and administered by research staff in the participant’s home language.

Ethical considerations

Ethical approval was obtained from the human research ethics committees of the University of Cape Town (ref. no. 245/2008), the University of the Witwatersrand (ref. no. 080710), the University of KwaZulu-Natal (ref. no. BF109/08) and the University of Limpopo (ref. no. MREC/P/110/2009). When study procedures identified HIV infection, steps were taken to counsel participants, ensure timely participant disclosure to a trusted adult, and link participants to care.
Efforts were made to reduce the risk of HIV infection of enrolled participants, and assistance was provided to participants with syphilis or those who became pregnant while enrolled. There was engagement with participating community representatives, including community advisory board youth representatives, as recommended for adolescent prevention trials.10–16

Statistical analysis
Data were analysed using Stata 14.0 (StataCorp, USA). Participants were divided into two age groups, using age at enrolment (12 - 15 and 16 - 17 years), based on the different inclusion criteria regarding sexual activity. The assessment of understanding score was calculated as the number of correct answers to 13 questions. Bivariate analysis employed Student’s t-test, Fisher’s exact test and the χ² test of proportions, as appropriate; for intra-individual comparisons of measures taken at baseline and 9 months, McNemar’s χ² test, McNemar’s exact test and paired t-tests were used. The incidences of pregnancy and HIV seroconversion were calculated as the number of incidence events divided by total person-time of follow-up. Survival analyses, including Kaplan-Meier tables and Cox’s proportional hazards models, were used to determine factors associated with loss to follow-up in the cohort. All statistical tests were two-sided at α=0.05. Owing to delayed starts and study funding contracts, the study procedures were halted for a number of participants (mainly from two sites) prior to their scheduled follow-up completion. These individuals completed their vaccine schedules, but no further study data were collected. Analyses of retention (defined as completion of all five study visits), vaccine completion and follow-up behaviours excluded these participants.

Results
Cohort description
Screening and enrolment took place from November 2009 to October 2010, with staggered site initiation and mean recruitment of 168 participants per site over 8.4 months (Fig. 1). Of the 961 adolescents screened across the five sites, 844 (87.8%) were enrolled (Table 1). The majority of adolescents who enrolled were in the 12 - 15-year-old age group (81%). The median age of enrolled participants was 14 years (interquartile range (IQR) 13 - 15) at screening, and 61% were female. The mean assessment of understanding score at enrolment was 11.3 out of 13. The most common reasons for failure of screening across all sites were adolescents who had not engaged in sexual activity.

Table 1. Baseline demographics and sexual risk behaviour by age group

<table>
<thead>
<tr>
<th>Variable</th>
<th>Age (years), n (%)</th>
<th>12 - 15 (N=684, 81%)</th>
<th>16 - 17 (N=519, 19%)</th>
<th>Total (N=843)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender female, n (%)</td>
<td>420 (61)</td>
<td>90 (57)</td>
<td>510 (61)</td>
<td>0.27</td>
<td></td>
</tr>
<tr>
<td>Ever had sex, n (%)</td>
<td>58/674 (9)</td>
<td>135/157 (86)</td>
<td>193/381 (23)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Age (years) at first sex, median (IQR)</td>
<td>14 (12 - 15)</td>
<td>15 (15 - 16)</td>
<td>15 (14 - 16)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Number of sexual partners, median (IQR)</td>
<td>1 (1 - 1)</td>
<td>1 (1 - 2)</td>
<td>1 (1 - 2)</td>
<td>0.16</td>
<td></td>
</tr>
<tr>
<td>Of all the times had sex, frequency of condom use, n (%)</td>
<td>30/57 (53)</td>
<td>94/135 (70)</td>
<td>124/192 (64)</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>Always</td>
<td>3/57 (5)</td>
<td>5/135 (4)</td>
<td>10/192 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usually</td>
<td>3/57 (5)</td>
<td>16/135 (12)</td>
<td>19/192 (10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rarely</td>
<td>1/57 (2)</td>
<td>6/135 (4)</td>
<td>7/192 (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>18/57 (32)</td>
<td>143/192 (10)</td>
<td>32/192 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever engaged in transactional sex, n (%)</td>
<td>2/55 (4)</td>
<td>2/135 (1.5)</td>
<td>4/190 (2)</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>Received</td>
<td>1/57 (2)</td>
<td>3/133 (2)</td>
<td>4/190 (2)</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Given</td>
<td>32/56 (57)</td>
<td>79/134 (59)</td>
<td>111/190 (58)</td>
<td>0.82</td>
<td></td>
</tr>
<tr>
<td>Ever had sex with someone without knowing their HIV status, n (%)</td>
<td>6/57 (11)</td>
<td>11/134 (8)</td>
<td>17/191 (9)</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>Has someone ever used force to make you have sex, n (%)</td>
<td>2/56 (4)</td>
<td>3/129 (2)</td>
<td>5/185 (3)</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>Ever had an STI, n (%)</td>
<td>3/57 (5)</td>
<td>16/132 (12)</td>
<td>19/189 (10)</td>
<td>0.19</td>
<td></td>
</tr>
</tbody>
</table>

IQR = interquartile range; STI = sexually transmitted infection.
aged 16 - 17 years not being sexually active (n=46 participants) or participants being lost to follow-up after arriving without a biological parent or legal guardian and then never returning or not being contactable afterwards (n=273).

Owing to delayed starts at the sites and study funding contracts, 256 participants (30%) were not enrolled in time to finish the full five visits. When those who completed the full 9 months of study time were compared with those who enrolled late, these participants did not differ in terms of age, gender or reporting at baseline ever having had sex. Baseline data from all 843 participants are presented in Table 1. Participants who could not complete 9 months of follow-up owing to termination of study procedures (n=256) were excluded from assessments of retention and vaccine completion (Fig. 2). This early closure mainly affected two sites.

Sexual risk behaviour and assessment of understanding

Table 1 shows baseline sexual risk behaviour of participants as reported in self-administered questionnaires by the two eligibility age groups, 12 - 15 and 16 - 17 years. Of the participants, 23% reported ever having had sex, of whom 9% were 12 - 15 years old. Despite the eligibility requirement, only 86% of 16 - 17-year-olds reported sexual activity at baseline. The median age of sexual debut was lower in the younger age group (14 v. 15 years; p=0.0001). Consistent condom use increased with age, with 12 - 15-year-old sexually active participants significantly less likely to have used condoms than 16 - 17-year-olds (10% v. 32%, respectively; p=0.002). There were no statistically significant differences across other baseline sexual risk indicators between the age groups.

Table 2 reports changes in sexual risk behaviour from baseline to study end. This analysis was restricted to those participants who attended the study visit at month 9, and mainly focused on questions regarding sexual activity ‘in the past 6 months’. Within the age groups, the only statistically significant change was a reported increase in the number of 12 - 13-year-olds ever having had sex (p=0.01). However, as the numbers of match pairs reporting sexual activity were small, we also assessed changes across all participants at baseline and those retained at 9 months. Borderline improvement was noted in the proportions of participants who reported using condoms ‘always’ or ‘usually’ from baseline to study end (74% to 86%; p=0.05), while the number who reported ‘never’ using a condom fell significantly (12% to 1.4%; p=0.001). Compared with baseline, at the end of the study more participants reported having had sex with someone known to be HIV-positive (0% to 4%; p=0.03). Mean assessment of study procedure understanding scores decreased from 11.3 at baseline to 11.1 at 9 months (paired t-test: p=0.001), and this decrease was noted across both age groups.

Cohort retention

Fig. 3 depicts a Kaplan-Meier curve of participant retention over the study period, stratified by the two age groups. Considering only the participants who had the potential to complete all five sessions before study termination, overall retention (defined as attendance at all five study visits) was 89%. There was no difference in retention between the two groups (88% in the younger group v. 87%; log-rank test: p=0.55). Retention was not associated with gender or with reporting being sexually active at baseline (Table 3); however, attrition had a borderline association with baseline reports of having ever had sex while drunk or under the influence of drugs (p=0.06) (Table 3). There was no association between baseline assessment of understanding
scores and attrition (p=0.94). Reasons why some participants were lost to follow-up were not recorded.

HIV, STI and pregnancy incidence
Ten pregnancies occurred over the study period, with a total of 511.6 years of follow-up time accumulated across all five sites, giving an incidence rate of 1.95 per 100 person-years (95% confidence interval (CI) 0.9 - 3.6). Five of the 10 pregnant participants reported contraceptive use at enrolment, 3 using male condoms, 3 using the female condom, and 3 using injectable contraceptives (one participant used two of these methods, and one three). Females who had their sexual debut prior to study participation were more likely to become pregnant (odds ratio 5.09, 95% CI 1.4 - 18.21). Six of the 10 participants who became pregnant prior to the 6- or 9-month appointment were lost to follow-up.

The trial was conducted in areas with a high HIV burden, and HIV seroconversion occurred in two participants, although one participant seroconverted between screening and enrolment, suggesting that she was in the window period at screening. Based on the one incident infection, which was detected at month 9, the incidence was 0.20 per 100 person-years (95% CI 0.005 - 1.1). Both seroconverters were female, aged 13 and 15 years. Syphilis testing was conducted at each study visit and overall only one participant tested positive for syphilis, at the time of enrolment.

Vaccinations
Overall, 826 (98%) of participants with parental/guardian consent agreed to receive the HPV vaccine. Of the 580 participants who were consented and enrolled at least 9 months prior to study termination, 532 (92%) completed the full HPV vaccination schedule.

Discussion
This study proved the feasibility of recruiting and retaining adolescents in a clinical trial in which a multidose ‘STI’ vaccine was administered to participants, emulating an adolescent HIV vaccine trial. This study supports a model of adolescent inclusion in HIV vaccine trials where, once a potential vaccine regimen is considered safe and immunogenic in adult efficacy studies, the eligibility age for study participation may be ‘rolled down’ to 16 - 18 years in order to be inclusive of younger participants (shown in Fig. 4).\textsuperscript{[25,51]} Phase 1 - 2 bridging studies for safety and immunogenicity can then be designed for younger adolescent age groups in whom sexual activity has not yet commenced. Minor adolescent participants could then contribute to safety and immunogenicity data without contributing to efficacy data.

To date, HIV prevention trials have targeted adults at high risk for HIV acquisition by enrolling individuals who have multiple sex partners, partners of unknown or positive HIV serostatus, or sex without condoms. In this study, we asked only that older adolescents (aged 16 - 17 years) be sexually active, as 16 is the age of consent to sex in SA and inclusion of such a criterion would have had legal implications. Sexual activity is no longer a reportable offence when younger adolescents engage in sex with peers, or with an older partner where the age difference is less than 2 years; however, parental and societal pressure remains a barrier to high-risk adolescents acknowledging sexual activity and taking part in such trials when parental consent is required.\textsuperscript{[53,54]} Although 961 adolescents were recruited in this study, sexual eligibility criteria combined with the need for parental consent may have influenced the age distribution, as the majority had not initiated sexual activity and only 19% of the enrolled sample fell within the 16 - 17-year age group. There is a need for study investigators, institutional ethics bodies and regulators to consider alternative approaches for the inclusion of older adolescents that do not involve parental consent.

The trial was modelled on previous adolescent HPV vaccine licensure studies, and in order to mimic the likely consent approach for an HIV vaccine trial, participants in our study required parental/guardian consent to enrol. In the VDGs, the HPV vaccine was portrayed as a vaccine to prevent a sexually transmitted infection in order to fit with a simulated HIV vaccine design. At the time of protocol design, consultations and discussions were held around the dynamic ethicolegal framework of SA research, laws and involvement of minors, and these discussions have led to a number of important publications.\textsuperscript{[11,14,17]} This study suggests that the requirement for

Table 3. Bivariate association of baseline demographics and sexual risk behaviours with attrition

<table>
<thead>
<tr>
<th>Variable</th>
<th>Bivariate analysis</th>
<th>HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at enrolment</td>
<td></td>
<td>1.09 (0.93 - 1.29)</td>
<td>0.25</td>
</tr>
<tr>
<td>Gender female</td>
<td></td>
<td>0.59 (0.25 - 1.39)</td>
<td>0.66</td>
</tr>
<tr>
<td>Ever had sex</td>
<td></td>
<td>1.36 (0.67 - 2.384)</td>
<td>0.29</td>
</tr>
<tr>
<td>Ever engaged in transactional sex</td>
<td></td>
<td>-</td>
<td>1.00</td>
</tr>
<tr>
<td>Ever had sex with someone without knowing their HIV status</td>
<td></td>
<td>0.92 (0.34 - 2.41)</td>
<td>0.86</td>
</tr>
<tr>
<td>Ever had sex while drunk or under the influence of a drug</td>
<td></td>
<td>2.97 (0.97 - 9.12)</td>
<td>0.06</td>
</tr>
</tbody>
</table>

HR = hazard ratio; CI = confidence interval.
parental/guardian consent coupled with the requirement for older adolescents to be sexually active may have been an obstacle to recruitment of high-risk adolescents, owing to awareness of sexual activity on the part of the parents/guardians and resultant discomfort between the adults and the adolescents. Had a proportion of participants in the 16 - 17-year-old age group been pre-stipulated, recruitment may have been more challenging. Going forward, this ‘dilution of incidence’ effect should be catered for by limiting the number of adolescents in the adult trial (Fig. 4) and/or factoring in a lower incidence contribution from this age group. Alternatively, ways should be explored to identify high-risk young individuals without requiring disclosure of behaviours to guardians.

**HIV incidence**

Overall, self-reported sexual risk behaviour at study onset was low, and HIV incidence was particularly low relative to SA standards at 0.20 per 100 person-years. This is lower than the estimated incidence of 0.56/100 person-years in 15 - 18-year-oldsmathematically derived from prevalence data by Shishana et al.,24 as well as lower than that observed in a 16 - 20-year-old cohort study in a similar setting (9.2/100 person-years).21 It also contrasts with vaccine preparedness studies, where behavioural data suggest that individuals volunteering for vaccine-related research may be more likely to be at risk of HIV than those who do not volunteer. Smit et al.24 compared risk profiles of individuals volunteering for an HIV vaccine preparedness cohort with those of a community sample. Adjusting for age, gender, education and risk perception, cohort participants were younger, more likely to have been treated for an STI, and less likely to use condoms. Jaspanteal.23 also found high-risk levels in an 11 - 19-year-old adolescent cohort, with one-third having experienced sexual debut (at a mean age of 14.6 years) and an HIV prevalence rate of 10.6%.24 In a 12-month follow-up of 14 - 17-year-olds, Jaspanteal.24 found reports of high-risk behaviours and, although no HIV seroconversions occurred, the occurrence of five pregnancies supported reports of unprotected sex.24 Parental/guardian consent was waived in this latter study. Furthermore, participation of adolescents in this study who were sexually active with full parental knowledge may imply that they were more self-efficacious individuals, and so more likely to engage in safer sex practices.

**Sexual risk behaviour**

The study findings highlight the challenges of collecting accurate, authentic sexual risk behaviour data from adolescents. The discrepancy between the eligibility requirement for sexual activity in 16 - 17-year-olds and the reporting of this behaviour in only 87% of the cohort may reflect either misunderstanding by some adolescents or inaccuracies around behaviour reporting at the time of enrolment or questionnaire completion. Recent prevention trials in adult women in SA have highlighted that a strong reason for individual participation is the access to improved health services that clinical research offers. In this case, access to an otherwise unavailable vaccine may have prompted young people to report behaviours inaccurately.

At baseline, reported condom use improved with increasing age. This finding suggests that adolescents become more skilled at negotiating condom use as they become more sexually experienced, while younger adolescents may be less prepared for or anticipating of sex. However, sexual activity in the youngest age group was infrequent and results from this group should be interpreted with caution. By the end of the study, improvements in condom use were observed, which may be due to increasing age, preparedness for and experience with sex (as before) or to study participation, as risk reduction counselling, HIV testing and condoms were provided at every visit.

In addition, by the end of the study more participants reported knowing their partners’ serostatus. This may be a function of more prevalent testing as adolescents get older and begin to engage with older partners, or also a result of study participation. Risk behaviours are studied repeatedly throughout prevention trials because the concern remains that participation may cause sexual disinhibition, where individuals exhibit increased risk behaviour owing to perceived protection. This concern is repeatedly raised in the context of youth involvement in clinical prevention trials. However, clinical trials in adults have consistently shown reduced risky behaviour during trial participation, and although adolescents are more challenging to study, owing to natural developmental and behaviour changes, our data showed no evidence of behavioural disinhibition.

In contrast to HIV rates, the pregnancy incidence in this cohort was relatively high. This suggests the practice of condomless sex coupled with age-related lower HIV risk networks. It is possible that young women are on the brink of exposure to sexual partners who will place them at risk of HIV infection as well as pregnancy, again emphasising the urgent need for a protective vaccine before this occurs.

**Trial retention**

Retention in the study was 89%. Previous studies reported retention rates of 87% in a 16 - 20-year-old cohort21 and 82% in a 14 - 17-year-old cohort,24 each followed for 12 months. Adolescence is a challenging age for trial retention owing to competing priorities, busy schedules and structural impediments, as well as evolving autonomy and independence. Capacity building was initially undertaken to ensure that all trial sites were competent to enrol adolescents and that all would be safe, friendly and attractive to adolescents.24 Perception of the value of the HPV vaccine, both costly and at the time inaccessible to most SA adolescents, may have contributed to the high retention
rate. Albiet unavailable, the vaccine used was known to be safe and effective, and this may have contributed to the high retention rate. It is not known how willingness of this age group to participate would have been affected if an experimental vaccine product of unknown efficacy had been offered.

Although the marginal decrease in assessment of understanding scores across the study period was statistically significant, we doubt that it is clinically significant. Regardless, this is a reminder that informed consent is an ongoing process that should be informally evaluated at every study visit. While vaccine discussion groups can bolster understanding, the way in which information is initially imparted and ongoing reminders of details over time are particularly important for long clinical trials. This may be especially true for adolescents, who can have difficulty in grasping information, and concepts should be revisited to ensure ongoing informed consent.

It is worth noting here that SA now conducts a national HPV vaccination programme in adolescents, and HPV vaccine uptake and completion rates have been above and above those reported from other countries.24-26 Qualitative focus group research in SA had highlighted the concerns of mothers regarding agreement to HPV vaccination of their daughters,41 yet this did not appear to affect behaviour in the present study, with 98% of participants and their parents opting to receive the HPV vaccine. This is remarkable, because the HPV vaccine was framed in this study as a means to prevent STL rather than the more palatable cancer prevention message.

This study augurs well for an extended vaccine schedule in adolescents, providing useful information both for HPV vaccine roll-out in SA and for planning future adolescent HPV vaccine trials.37-40 This is particularly relevant in the context of the phase IIb/III HVTN 702 vaccine trial in SA, which will evaluate the efficacy and safety of a clad C ALVAC HIV and bivalent subtype C gp120/MF59 vaccine. Success in the phase IIb/III trial will pave the way for extension of the trial to adolescent participants. If the adolescent trial is successful, there could be potential for an effective, school-based, dual HPV/ HIV vaccine programme in SA.

Conclusions

The use of an HPV vaccine as a surrogate for an HIV vaccine has shown that adolescents aged 12 - 17 years can be successfully and easily recruited, enrolled and retained in clinical prevention trials in both rural and peri-urban SA, including trials framed as STI prevention (Fig. 3). In this study, the parental/guardianship consent strategy, combined with sexual-risk eligibility criteria, may have acted as a barrier to the enrolment of older high-risk adolescents. This suggests that HIV prevention studies enrolling high-risk, sexually-active adolescents must carefully consider the most appropriate consent approach. National ethical guidelines allow a waiver of parental/guardianship consent for adolescent studies where specific criteria are met, including that study procedures pose minimal risk. SA is currently enrolling adults only into the first HIV vaccine licensure study.47 It is clear that should this vaccine be even partially efficacious, the question of licensure in adolescents will be key. One option for HIV vaccine trials is that minor adolescent participants could contribute safety and immunogenicity data only without contributing to efficacy data, but there may be alternative approaches to include older at-risk adolescents that will require the consent strategy to be discussed with institutional ethics bodies and the regulators who ultimately license the product.

Acknowledgements. We acknowledge the importance of a capacity-building grant from the Bill and Melinda Gates Foundation together with the European and Developing Countries Clinical Trials Partnership (EDCTP). The grant allowed the successful building of capacity for safe and effective adolescent clinical trials in six SA sites. We also sincerely thank Merck Sharp & Dohme (MSD) for their generous donation of Gardasil HPV vaccine sufficient for all the adolescents in the study. We also thank all the clinical teams and terrific study co-ordinators, who made the experience safe and friendly for the participants. Finally, we acknowledge all the young South African villagers and their guardians who helped to contribute this work to your volunteering.

Author contributions. Conception, design and site oversight: LGB, GG, GC, CS, AS; collection of data and assembly: MW, MHL, TB, MM, MN; data analysis and interpretation: KM, PS; manuscript writing and editing: all authors; final approval of manuscript: all authors

Funding. Funding for this work was provided by the EDCTP (grant no. CT.2006.33111.004) and the Bill & Melinda Gates Foundation.

Conflicts of interest. None. MSD was not involved in the design, analysis or final preparation of the manuscript.


Accepted 14 November 2017.